US6515014B2
(en)
|
1995-06-02 |
2003-02-04 |
G. D. Searle & Co. |
Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US5567828A
(en)
*
|
1995-06-07 |
1996-10-22 |
Eli Lilly And Company |
Compounds and compositions with nitrogen-containing non-basic side
|
WO1996041645A1
(en)
|
1995-06-12 |
1996-12-27 |
G.D. Searle & Co. |
Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
|
US5700816A
(en)
*
|
1995-06-12 |
1997-12-23 |
Isakson; Peter C. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
|
PT880362E
(pt)
|
1996-02-13 |
2005-10-31 |
Searle & Co |
Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4
|
US5908858A
(en)
|
1996-04-05 |
1999-06-01 |
Sankyo Company, Limited |
1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
|
FR2751966B1
(fr)
*
|
1996-08-01 |
1998-10-30 |
Union Pharma Scient Appl |
Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
|
TWI235060B
(en)
|
1996-10-15 |
2005-07-01 |
Searle & Co |
Pharmaceutical compositions comprising substituted pyrazolyl benzenesulfonamide derivatives for use in treating or preventing an epithelial cell-derived neoplasia
|
ES2215242T3
(es)
*
|
1996-11-19 |
2004-10-01 |
Amgen Inc. |
Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
|
TR199901703T2
(xx)
*
|
1996-11-19 |
2000-07-21 |
G.D. Searle & Co. |
Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
|
WO1998037235A1
(en)
|
1997-02-24 |
1998-08-27 |
Cornell Research Foundation, Inc. |
Method of screening agents as candidates for drugs or sources of drugs
|
ATE271547T1
(de)
*
|
1997-03-14 |
2004-08-15 |
Merck Frosst Canada Inc |
Pyridazinone als inhibitoren von cyclooxygenase-2
|
US6004960A
(en)
*
|
1997-03-14 |
1999-12-21 |
Merck Frosst Canada, Inc. |
Pyridazinones as inhibitors of cyclooxygenase-2
|
WO1998050075A1
(en)
*
|
1997-05-07 |
1998-11-12 |
Algos Pharmaceutical Corporation |
Cox-2 inhibitors in combination with nmda-blockers for treating pain
|
US6013674A
(en)
*
|
1997-06-02 |
2000-01-11 |
Eli Lilly And Company |
Cell adhesion inhibitors
|
ES2231757T3
(es)
*
|
1997-09-05 |
2005-05-16 |
Glaxo Group Limited |
Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina.
|
RS49982B
(sr)
*
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
CN1279682A
(zh)
|
1997-10-20 |
2001-01-10 |
霍夫曼-拉罗奇有限公司 |
双环激酶抑制剂
|
FR2770131A1
(fr)
*
|
1997-10-27 |
1999-04-30 |
Union Pharma Scient Appl |
Nouvelle association pharmaceutique a activite analgesique
|
FR2771005B1
(fr)
*
|
1997-11-18 |
2002-06-07 |
Union Pharma Scient Appl |
Nouvelle association pharmaceutique a activite analgesique
|
US6025353A
(en)
*
|
1997-11-19 |
2000-02-15 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
|
US7041694B1
(en)
|
1997-12-17 |
2006-05-09 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
HUP0100310A3
(en)
*
|
1997-12-22 |
2002-11-28 |
Euro Celtique Sa |
A method of preventing abuse of opioid dosage forms
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
CA2314893C
(en)
|
1997-12-22 |
2005-09-13 |
Euro-Celtique, S.A. |
Opioid agonist/antagonist combinations
|
GB9804886D0
(en)
*
|
1998-03-06 |
1998-04-29 |
Merck Sharp & Dohme |
Therapeutic combination
|
WO1999051587A1
(fr)
*
|
1998-04-01 |
1999-10-14 |
Ono Pharmaceutical Co., Ltd. |
Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif
|
ATE482945T1
(de)
|
1998-05-26 |
2010-10-15 |
Chugai Pharmaceutical Co Ltd |
Heterozyklische indolderivate und mono- oder diazaindol-derivate
|
KR100295206B1
(ko)
*
|
1998-08-22 |
2001-07-12 |
서경배 |
디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
|
TW587079B
(en)
*
|
1998-09-25 |
2004-05-11 |
Almirall Prodesfarma Ag |
2-phenylpyran-4-one derivatives
|
JP3420751B2
(ja)
*
|
1998-11-03 |
2003-06-30 |
グラクソ グループ リミテッド |
選択的cox‐2インヒビターとしてのピラゾロピリジン誘導体
|
CA2351224A1
(en)
*
|
1998-11-12 |
2000-05-25 |
Algos Pharmaceutical Corporation |
Cox-2 inhibitors in combination with nmda-blockers for treating pain
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US6649645B1
(en)
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
ATE261444T1
(de)
|
1999-02-27 |
2004-03-15 |
Glaxo Group Ltd |
Pyrazolopyridine
|
AU3885901A
(en)
*
|
1999-09-21 |
2001-04-24 |
Emory University |
Methods and compositions for treating platelet-related disorders
|
KR100793668B1
(ko)
*
|
1999-12-08 |
2008-01-10 |
파마시아 코포레이션 |
강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
|
GB9930358D0
(en)
|
1999-12-22 |
2000-02-09 |
Glaxo Group Ltd |
Process for the preparation of chemical compounds
|
EP1263759B1
(de)
|
1999-12-24 |
2010-09-08 |
Aventis Pharma Limited |
Azaindole
|
DE60135441D1
(de)
|
2000-02-08 |
2008-10-02 |
Euro Celtique Sa |
Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten
|
EP1299104B1
(de)
|
2000-02-08 |
2009-05-13 |
Euro-Celtique S.A. |
Missbrauchssichere orale opioid-agonist zubereitungen
|
PE20011333A1
(es)
|
2000-03-16 |
2002-01-16 |
Almirall Prodesfarma Ag |
Derivados de 2-fenilpiran-4-ona como inhibidores de ciclooxigenasa 2
|
WO2001081332A2
(en)
|
2000-04-25 |
2001-11-01 |
Pharmacia Corporation |
2-fluorobenzenesulfonyl compounds for the treatment of inflammation
|
WO2001087880A1
(fr)
*
|
2000-05-15 |
2001-11-22 |
Grelan Pharmaceutical Co., Ltd. |
Derives de 1-(benzathiazol-2-yl)pyrazole et inhibiteurs de cox-2 en contenant
|
WO2002005848A2
(en)
*
|
2000-07-13 |
2002-01-24 |
Pharmacia Corporation |
Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
PT1303265E
(pt)
|
2000-07-20 |
2007-10-09 |
Lauras As |
''utilização de inibidores da cox-2 como imuno-estimulantes, no tratamento do vih ou da sida''
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
PE20020506A1
(es)
*
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
PT1347963E
(pt)
*
|
2000-12-05 |
2004-12-31 |
Hoffmann La Roche |
Derivados de benzofurano e de benzotiofeno como inibidores selectivos da cox-2
|
US6919352B2
(en)
|
2000-12-15 |
2005-07-19 |
Smithkline Beecham Corporation |
Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
|
DE60112330T2
(de)
|
2000-12-15 |
2006-04-13 |
Glaxo Group Ltd., Greenford |
Pyrazolopyridinderivate
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
US7153855B2
(en)
|
2001-03-08 |
2006-12-26 |
Smithkline Beecham Corporation |
Pyrazolopyridinyl pyrimidine therapeutic compounds
|
US7034030B2
(en)
|
2001-03-30 |
2006-04-25 |
Smithkline Beecham Corporation |
Pyralopyridines, process for their preparation and use as therapeutic compounds
|
US7695736B2
(en)
|
2001-04-03 |
2010-04-13 |
Pfizer Inc. |
Reconstitutable parenteral composition
|
WO2002083672A1
(en)
|
2001-04-10 |
2002-10-24 |
Smithkline Beecham Corporation |
Antiviral pyrazolopyridine compounds
|
ES2242028T3
(es)
|
2001-04-27 |
2005-11-01 |
Smithkline Beecham Corporation |
Derivados de pirazolo(1,5-a)piridina.
|
US6756498B2
(en)
|
2001-04-27 |
2004-06-29 |
Smithkline Beecham Corporation |
Process for the preparation of chemical compounds
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
DE60238756D1
(de)
|
2001-05-11 |
2011-02-10 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
TWI224101B
(en)
|
2001-06-20 |
2004-11-21 |
Wyeth Corp |
Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
|
WO2003000253A1
(en)
|
2001-06-20 |
2003-01-03 |
Wyeth |
Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
CN1518550A
(zh)
|
2001-06-21 |
2004-08-04 |
ʷ��˿�������ȳ�ķ����˾ |
用于预防和治疗疱疹病毒感染的咪唑并[1,2-a]吡啶衍生物
|
GB0115109D0
(en)
*
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
CA2454328C
(en)
*
|
2001-07-18 |
2008-03-18 |
Christopher D. Breder |
Pharmaceutical combinations of oxycodone and naloxone
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
CA2457361C
(en)
|
2001-08-06 |
2008-11-04 |
Christopher Breder |
Opioid agonist formulations with releasable and sequestered antagonist
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
JP2005508955A
(ja)
|
2001-10-05 |
2005-04-07 |
スミスクライン ビーチャム コーポレーション |
ヘルペスウイルス感染の治療で使用されるためのイミダゾ−ピリジン誘導体
|
GB0124934D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124931D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124938D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124936D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124941D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124933D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124939D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124932D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
WO2003050120A1
(en)
|
2001-12-11 |
2003-06-19 |
Smithkline Beecham Corporation |
Pyrazolo-pyridine derivatives as antiherpes agents
|
WO2003055873A1
(en)
|
2001-12-21 |
2003-07-10 |
H. Lundbeck A/S |
Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
|
US20030212138A1
(en)
*
|
2002-01-14 |
2003-11-13 |
Pharmacia Corporation |
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
US6653346B1
(en)
*
|
2002-02-07 |
2003-11-25 |
Galileo Pharmaceuticals, Inc. |
Cytoprotective benzofuran derivatives
|
US7078541B2
(en)
*
|
2002-02-07 |
2006-07-18 |
Galileo Pharmaceuticals, Inc. |
Benzofuran derivatives
|
EP1474395B1
(de)
*
|
2002-02-12 |
2007-10-17 |
Smithkline Beecham Corporation |
Nicotinamide und deren verwendung als p38 inhibitoren
|
EP2425821B1
(de)
|
2002-04-05 |
2017-05-10 |
Euro-Celtique S.A. |
Pharmazeutische Zubereitung mit Oxycodon und Naloxon
|
AU2003230965B2
(en)
|
2002-04-17 |
2008-02-21 |
The Cleveland Clinic Foundation |
Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
|
ES2375181T3
(es)
|
2002-05-09 |
2012-02-27 |
The Brigham And Women's Hospital, Inc. |
1l 1rl-1 como un marcador de enfermedades cardiovasculares.
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
US6960611B2
(en)
*
|
2002-09-16 |
2005-11-01 |
Institute Of Materia Medica |
Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof
|
EP2422773A3
(de)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestriermitteluntereinheit und zugehörige Zusammensetzungen und Verfahren
|
JP2006504728A
(ja)
|
2002-10-03 |
2006-02-09 |
スミスクライン ビーチャム コーポレーション |
ピラソロピリジン誘導体系治療用化合物
|
US7255860B2
(en)
|
2002-10-08 |
2007-08-14 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
|
DE60335957D1
(de)
*
|
2002-10-08 |
2011-03-17 |
Rinat Neuroscience Corp |
Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
|
WO2004052853A2
(en)
|
2002-12-10 |
2004-06-24 |
Wyeth |
Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
MXPA05006287A
(es)
|
2002-12-10 |
2005-09-08 |
Wyeth Corp |
Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
|
CN1726190A
(zh)
|
2002-12-10 |
2006-01-25 |
惠氏公司 |
作为纤溶酶原激活物抑制剂-1(pai-1)的抑制剂的取代3-羰基-1h-吲哚-1-基乙酸衍生物
|
UA80453C2
(en)
|
2002-12-10 |
2007-09-25 |
|
Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
CA2509191A1
(en)
|
2002-12-10 |
2004-06-24 |
Wyeth |
Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
CA2509605C
(en)
|
2002-12-13 |
2010-10-05 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
CA2921578C
(en)
*
|
2002-12-24 |
2017-02-14 |
Rinat Neuroscience Corp. |
Anti-ngf antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
EP1594441B1
(de)
|
2003-02-19 |
2010-12-15 |
Rinat Neuroscience Corp. |
Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
GB0308186D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308201D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308185D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
WO2005009342A2
(en)
*
|
2003-07-16 |
2005-02-03 |
Pharmacia Corporation |
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
|
GB0318814D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
EP3081214A3
(de)
|
2003-08-29 |
2016-11-16 |
The Brigham And Women's Hospital, Inc. |
Zellnekrosehemmer
|
WO2005023189A2
(en)
*
|
2003-09-03 |
2005-03-17 |
Pharmacia Corporation |
Method of cox-2 selective inhibitor and nitric oxide-donating agent
|
US7442805B2
(en)
|
2003-09-25 |
2008-10-28 |
Wyeth |
Substituted sulfonamide-indoles
|
US7265148B2
(en)
|
2003-09-25 |
2007-09-04 |
Wyeth |
Substituted pyrrole-indoles
|
US7420083B2
(en)
|
2003-09-25 |
2008-09-02 |
Wyeth |
Substituted aryloximes
|
US7141592B2
(en)
|
2003-09-25 |
2006-11-28 |
Wyeth |
Substituted oxadiazolidinediones
|
US7268159B2
(en)
|
2003-09-25 |
2007-09-11 |
Wyeth |
Substituted indoles
|
US7342039B2
(en)
|
2003-09-25 |
2008-03-11 |
Wyeth |
Substituted indole oximes
|
PL1663229T3
(pl)
|
2003-09-25 |
2010-09-30 |
Euro Celtique Sa |
Farmaceutyczne kombinacje hydrokodonu i naltreksonu
|
US7446201B2
(en)
|
2003-09-25 |
2008-11-04 |
Wyeth |
Substituted heteroaryl benzofuran acids
|
US7332521B2
(en)
|
2003-09-25 |
2008-02-19 |
Wyeth |
Substituted indoles
|
US7411083B2
(en)
|
2003-09-25 |
2008-08-12 |
Wyeth |
Substituted acetic acid derivatives
|
US7534894B2
(en)
|
2003-09-25 |
2009-05-19 |
Wyeth |
Biphenyloxy-acids
|
US7582773B2
(en)
|
2003-09-25 |
2009-09-01 |
Wyeth |
Substituted phenyl indoles
|
US7163954B2
(en)
|
2003-09-25 |
2007-01-16 |
Wyeth |
Substituted naphthyl benzothiophene acids
|
US7351726B2
(en)
|
2003-09-25 |
2008-04-01 |
Wyeth |
Substituted oxadiazolidinediones
|
WO2005044227A1
(en)
*
|
2003-11-05 |
2005-05-19 |
Glenmark Pharmaceuticals Limited |
Topical pharmaceutical compositions
|
US20050100594A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Nilendu Sen |
Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
|
US7067159B2
(en)
|
2003-12-05 |
2006-06-27 |
New Chapter, Inc. |
Methods for treating prostate cancer with herbal compositions
|
ATE546734T1
(de)
|
2003-12-05 |
2012-03-15 |
Cleveland Clinic Foundation |
Risikomarker für eine herzkreislaufkrankheit
|
US7070816B2
(en)
|
2003-12-05 |
2006-07-04 |
New Chapter, Inc. |
Methods for treating prostatic intraepithelial neoplasia with herbal compositions
|
AU2004298486A1
(en)
|
2003-12-12 |
2005-06-30 |
Wyeth |
Quinolines useful in treating cardiovascular disease
|
EP1708718A1
(de)
|
2004-01-22 |
2006-10-11 |
Pfizer Limited |
Triazol-derivate zur hemmung der vasopressing-antagonistischen aktivität
|
GB0402143D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
KR20060135060A
(ko)
|
2004-04-07 |
2006-12-28 |
리나트 뉴로사이언스 코퍼레이션 |
신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
|
JP2007534740A
(ja)
*
|
2004-04-28 |
2007-11-29 |
ファイザー・インク |
バソプレッシンV1a受容体の阻害剤としての3−ヘテロシクリル−4−フェニル−トリアゾール誘導体
|
EP1604666A1
(de)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
|
DK1765292T3
(en)
|
2004-06-12 |
2018-01-02 |
Collegium Pharmaceutical Inc |
ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
|
RU2007106868A
(ru)
|
2004-08-23 |
2008-09-27 |
Вайет (Us) |
Оксазол-нафтиловые кислоты и их применение в качестве модуляторов ингибитора активатора плазминогена-1 (pai) для лечения тромбоза и сердечно-сосудистых заболеваний
|
CN101044127A
(zh)
|
2004-08-23 |
2007-09-26 |
惠氏公司 |
用作纤溶酶原激活剂抑制剂-1的噻唑基-萘基酸
|
BRPI0514549A
(pt)
|
2004-08-23 |
2008-06-17 |
Wyeth Corp |
ácidos de pirrol-naftila como inibidores de pai-1
|
US7622142B2
(en)
|
2004-09-14 |
2009-11-24 |
New Chapter Inc. |
Methods for treating glioblastoma with herbal compositions
|
WO2006041855A2
(en)
|
2004-10-04 |
2006-04-20 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
US20080051416A1
(en)
*
|
2004-10-05 |
2008-02-28 |
Smithkline Beecham Corporation |
Novel Compounds
|
WO2006042192A2
(en)
|
2004-10-06 |
2006-04-20 |
The Brigham And Womens's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
SI2213652T1
(sl)
*
|
2004-12-17 |
2015-03-31 |
The Trustees Of The University Of Pennsylvania |
Derivati stilbena in njihova uporaba za vezavo in prikaz amiloidnih plakov
|
US7858072B2
(en)
*
|
2004-12-17 |
2010-12-28 |
The Trustees Of The University Of Pennsylvania |
Stilbene derivatives and their use for binding and imaging amyloid plaques
|
US20060183758A1
(en)
*
|
2005-02-17 |
2006-08-17 |
Cb Research And Development, Inc. |
Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
|
EP1702558A1
(de)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Verfahren und Vorrichtung zur Darmtätigkeitserfassung
|
GB0512429D0
(en)
*
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
EP1915157A4
(de)
|
2005-08-02 |
2010-09-01 |
Nicox Sa |
Stickoxidverstärkende antimikrobielle verbindungen, zusammensetzungen und verwendungsverfahren
|
EP1919866A2
(de)
|
2005-08-17 |
2008-05-14 |
Wyeth a Corporation of the State of Delaware |
Substituierte indole und deren verwendung
|
US8119358B2
(en)
*
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
EP1954685A4
(de)
|
2005-11-16 |
2009-11-11 |
Nitromed Inc |
Furoxanverbindungen, zusammensetzungen und anwendungsverfahren
|
HUE056086T2
(hu)
|
2006-03-15 |
2022-01-28 |
Brigham & Womens Hospital Inc |
Gelszolin alkalmazása gyulladásos betegségek diagnosztizálására és kezelésére
|
EP2007705A4
(de)
|
2006-03-29 |
2011-09-07 |
Nicox Sa |
Stickstoffmonoxid verstärkende prostaglandinverbindungen, zusammensetzung und anwendungsverfahren
|
EP2030025A2
(de)
|
2006-06-07 |
2009-03-04 |
Tethys Bioscience, Inc. |
Mit arteriovaskulären ereignissen assoziierte marker und verfahren zu ihrer verwendung
|
KR20140079441A
(ko)
|
2006-06-19 |
2014-06-26 |
알파마 파머슈티컬스 엘엘씨 |
약제학적 조성물
|
TW200819426A
(en)
|
2006-08-31 |
2008-05-01 |
Lundbeck & Co As H |
Novel indane compounds
|
EA017171B1
(ru)
|
2006-12-22 |
2012-10-30 |
Рекордати Айерленд Лимитед |
КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
|
CA2676413A1
(en)
*
|
2007-01-19 |
2008-07-31 |
Mallinckrodt Inc. |
Diagnostic and therapeutic cyclooxygenase-2 binding ligands
|
ES2434215T3
(es)
|
2007-04-18 |
2013-12-16 |
Tethys Bioscience, Inc. |
Biomarcadores relacionados con la diabetes y métodos de uso de los mismos
|
BRPI0814542A2
(pt)
|
2007-07-12 |
2014-09-30 |
Tragara Pharmaceuticals Inc |
Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
GB2462022B
(en)
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
|
WO2010003963A1
(en)
*
|
2008-07-07 |
2010-01-14 |
Euro-Celtique S.A. |
Use of opioid antagonists for treating urinary retention
|
WO2010071865A1
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
US20100160351A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
JP5596364B2
(ja)
*
|
2009-02-19 |
2014-09-24 |
住友化学株式会社 |
含窒素有機化合物及びそれを用いた有機エレクトロルミネッセンス素子
|
JP5886632B2
(ja)
|
2009-03-10 |
2016-03-16 |
ユーロ−セルティーク エス.エイ. |
オキシコドンおよびナロキソンを含む即時放出医薬組成物
|
WO2011032175A1
(en)
|
2009-09-14 |
2011-03-17 |
Nuon Therapeutics, Inc. |
Combination formulations of tranilast and allopurinol and methods related thereto
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
CN103037829A
(zh)
|
2010-02-01 |
2013-04-10 |
儿童医院 |
用于治疗和预防再狭窄的远程缺血调节
|
CA2795053A1
(en)
|
2010-03-31 |
2011-10-06 |
The Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
AU2011291462A1
(en)
|
2010-08-19 |
2013-03-14 |
Zoetis Belgium S.A. |
Anti-NGF antibodies and their use
|
PL2826467T3
(pl)
|
2010-12-22 |
2018-01-31 |
Purdue Pharma Lp |
Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
|
ES2581323T3
(es)
|
2010-12-23 |
2016-09-05 |
Purdue Pharma Lp |
Formas de dosificación oral sólida resistentes a alteraciones
|
HUE044062T2
(hu)
|
2011-05-20 |
2019-09-30 |
Alderbio Holdings Llc |
Anti-CGRP készítmények és alkalmazásuk
|
CA2873214C
(en)
|
2012-05-11 |
2021-02-16 |
Reset Therapeutics, Inc. |
Carbazole-containing sulfonamides as cryptochrome modulators
|
AP2015008579A0
(en)
|
2013-02-05 |
2015-07-31 |
Purdue Pharma Lp |
Tamper resistant pharmaceutical formulations
|
US9725452B2
(en)
|
2013-03-15 |
2017-08-08 |
Presidents And Fellows Of Harvard College |
Substituted indoles and pyrroles as RIP kinase inhibitors
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
KR20160034352A
(ko)
|
2013-07-23 |
2016-03-29 |
유로-셀티큐 에스.에이. |
장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
EP3292213A1
(de)
|
2015-05-04 |
2018-03-14 |
Academisch Medisch Centrum |
Biomarker für den nachweis von aspirinunempfindlichkeit
|
KR102444717B1
(ko)
|
2016-04-15 |
2022-09-16 |
하. 룬드벡 아크티에셀스카브 |
인간화 항-pacap 항체 및 그의 용도
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
EP3852732A1
(de)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Peg-lipide und deren verwendung
|
WO2020061295A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
CA3209491A1
(en)
|
2021-03-15 |
2022-09-22 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
|
CA3229059A1
(en)
|
2021-08-27 |
2023-03-02 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|